Shukla Sanjay's Form 4 filing
aTYR PHARMA INC (ATYR) · filed Feb 4, 2026
- Accession no.
- 0001193125-26-038007
- Filed
- Feb 4, 2026
- Trade date
- Feb 3-4, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.67K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shukla SanjayCIK 0001671026 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Common Stock | MOption exerciseAcquired | +10,375 | –F2 | – | 157,298 | Direct | |
| Feb 4, 2026 | Common Stock | SSaleDisposed | −3,745 | $0.98 | −$3,670.1 | 153,553 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Common Stock | MOption exerciseDisposed | −10,375 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Restricted stock units convert into common stock on a one-for-one basis.
Referenced by the price of 1 transaction in Table I.